[Antimicrobial peptides: A new alternative for the treatment of aspergillosis] (Équipe Seksik/Sokol)

March 07 - 2024

C. Rochard, C. J. Bigot, V. Balloy, G. Hennequin, J. Guitard

Rev Mal Respir. 2024 Apr;41(4):283-288

Aspergillus fumigatus is the predominant fungal species causing pulmonary aspergillosis. The present-day anti-aspergillosis arsenal is limited, with a number of molecules occasioning severe side effects (amphotericin B) or provoking significant drug interactions (azole derivatives). Moreover, the recent emergence of azole-resistant A. fumigatus strains is a cause for concern. In this context, antimicrobial peptides (AMPs) are emerging as a promising therapeutic approach and alternative or complement to conventional antifungals.

St. Antoine Hospital

Kourilsky Building
34 rue Crozatier - 75012 Paris

Sorbonne Université Medicine
Saint-Antoine Site
27 rue Chaligny - 75012 Paris

This site uses cookies and gives you control over what you want to enable Accept all Personalize